BriaCell
1880 Century Park East, Suite #315
Los Angeles
California
90067
United States
Website: http://www.briacell.com/
85 articles about BriaCell
-
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
4/21/2021
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp.
-
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
3/30/2021
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May 17-21.
-
BriaCell Presents Clinical Data at 2021 Keystone Symposium
1/26/2021
BriaCell is pleased to announce the presentation of results from clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session held January 25-27 during the 2021 Keystone Symposium, “Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics,” a virtual scientific conference.
-
BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
1/12/2021
Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021 BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V: BCT ) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced br
-
BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
12/9/2020
BriaCell Therapeutics is pleased to announce the presentation results of the clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session held on December 9 – 11 during the 2020 San Antonio Breast Cancer Symposium
-
BriaCell Announces Collaboration with the National Cancer Institute
11/10/2020
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF ) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a Cooperative Resear
-
BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
10/21/2020
Overall Survival of 13.3 months inpatients,including 14 months in patients with Grade I/II tumors, suggesting clinical benefit;
-
BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11C
10/6/2020
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (" BriaCell " or the "Company") (TSX-V:BCT) (OTCQB:BCTXF ) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in a poster session on December 9 – 11 during the 2020 San Antonio Breast Cancer Symposium ® (SABCS), a virtual event. The po
-
Note from BriaCell Management – October is Breast Cancer Awareness Month
10/1/2020
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.
-
BriaCell to Present at the 3rd Annual Biologics World Nordic 2020
9/15/2020
BriaCell Therapeutics Corp. is announcing that Dr. Bill Williams, BriaCell’s President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual event held during September 30 – October 1, 2020.
-
BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation
9/4/2020
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that it has received a research grant from the Wiseman Cancer Research Foundation, a 501c(3) nonprofit organization based in Beverly Hills, CA. The research grants are awarded to individual scientists or en
-
BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease
6/24/2020
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining compositions and methods of developing novel multi-valent decoy receptors for diagnosis and treatment of coronavirus infection.
-
BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
6/22/2020
Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, with or without a PD-1 inhibitor. Patients with “moderately” or “well” differentiated tumors showed a higher rate of dis
-
BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June 2020
6/9/2020
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held on June 25 - 26, 2020.
-
BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting
5/29/2020
Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, showed no serious side effects and resulted in clinical responses in heavily pre-treated patients with metastatic breast cancer. Women with “moderately” or “well” differentiated tumors showed a higher rate of disease contr
-
BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
5/20/2020
BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining a novel vaccine platform to selectively deliver antigens of interest to immune cells to induce immune responses toward pathogens including SARS-CoV-2 virus or cancer cells, or reduce immune responses in the case of autoimmune or allergic diseases.
-
BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
5/20/2020
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO).
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
-
BriaCell Files Patent Application for Novel Therapeutics for Cancer
4/27/2020
BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the development and use of novel therapeutics that activate immune cells to selectively destroy the cancer cells or to selectively block cancer cells from inactivating immune cells.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.